Pipeline
Overview - Our Pipeline
               
SYN004

SYN004 is a recombinant chimeric monoclonal antibody (mAb) that binds specifically to the N-terminal portion of the human epidermal growth factor receptor (EGFR). SYN004 has the same pharmacological properties as cetuximab a leading oncology product for the treatment of colorectal and head and neck cancers. The glycan profile of SYN004 is appreciably less immunoreactive than that of cetuximab. Additionally, the sialic acid of the SYN004 is N-acetylneuraminic acid (NANA) instead of the N-glycolylneuraminic acid (NGNA) on cetuximab. As a consequence, SYN004 is proposed to be a safer product than cetuximab, while it has the same mechanism of action and similar efficacy to cetuximab. The phase I study of SYN004 has been conducting in the US in patients with solid tumors since Oct 2015, and will be completed in 2Q 2017.

SYN008

SYN008 is a biosimilar of Omalizumab (Xolair; a humanized anti-immunoglobulin E monoclonal antibody). It binds to the free IgE molecules in serum, thereby blocking the interaction between IgE and effector cells, which trigger the allergic response irrespective of allergen type. Stringent comparability studies between SYN008 and Omalizumab have been conducted and the investigational new drug (IND) application of SYN008 has been filed to the China Food and Drug Administration (CFDA) in Oct 2014. The phase I clinical trial has been completed in  Australia in Sep 2016.

SYN023

SYN-023 is a mixture of two anti-rabies humanized monoclonal antibodies, CTB-011 and CTB-012, which bind to 2 different antigenic sites on the rabies glycoprotein. SYN-023 is proposed for use in humans following exposure to the rabies virus. The proposed clinical indication is for post-exposure prophylaxis treatment of rabies in conjunction with rabies vaccine. The proposed mechanism of action is for the mAbs to bind to the rabies virus, which results in virus neutralization in a manner similar to an immune response producing neutralizing antibodies. SYN-023 has been shown to neutralize greater than 15 contemporary wildlife isolates of rabies virus collected in China and 10 isolates collected in the North American. The preclinical studies of SYN-023 have been completed. The Phase I study conducted in the US in healthy adult volunteers has been completed in Jun 2016. The phase II study has been conducting in the US since Aug 2016, and will be completed in 2Q 2017.